Evaluation of Canakinumab in High-Risk Former-Smokers

Summary

This phase II trial tests the impact of canakinumab on biologic samples (buccal, nasal, and blood) from former smokers with increased risk of cancer. Canakinumab blocks the activity of a protein called interleukin-1 beta (IL-1b), an agent of the inflammatory system and is used for the treatment of different non-cancer diseases (like auto-inflammatory diseases). Giving canakinumab may block the inflammatory system and could have positive effects to reduce cancer growth.

Timeline

Start

2024-03-11

Primary completion

2026-02-04

Completion

2026-05-26

Drugs

Indications